Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity

Author(s): Ewa Lech-Maranda, Ewa Robak, Anna Korycka, Tadeusz Robak

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 7 , Issue 10 , 2007

Become EABM
Become Reviewer
Call for Editor


Depsipeptide (FK228), a new histone deacetylase inhibitor, has been recently introduced into clinical trials. This agent shows interesting metabolic properties, novel mechanism of action, and is undergoing phase I-II clinical studies in hematopoietic malignancies and solid tumors. Mechanism of action, pharmacokinetics and anticancer activity of depsipeptide is the subject of this review.

Keywords: Epigenetic therapy, histone deacetylase inhibitors, depsipeptide (FK228), cutaneous T-cell lymphoma, solid tumors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1062 - 1069]
Pages: 8
DOI: 10.2174/138955707782110178
Price: $65

Article Metrics

PDF: 4